NO DECISIONDismissed97% confidenceGPT-5.4 (OpenAI)
Question
Will the results be positive?
Found
Reviewed
Summary
No trial-specific efficacy readout is public yet. ClinicalTrials.gov still lists SKYLINE-UC as recruiting, and Spyre said on April 10, 2026 that it will report SPY001 Part A induction topline results on April 13, 2026. With no released data framing this exact trial as positive or negative, outcome cannot be classified yet.
Sources
ClinicalTrialsclinicaltrials.gov
Study Details | NCT07012395 | A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
ClinicalTrials.gov lists SKYLINE-UC (NCT07012395) as a Phase 2 platform study in moderate to severe UC; the study remains recruiting.
View source
Sponsorglobenewswire.com
Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026
Spyre announced on April 10, 2026 that it will report SPY001 Part A induction topline results from the SKYLINE trial on April 13, 2026, indicating the readout was still pending.
View source